AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAY 8 - (NewsRx.com & NewsRx.net) -- Affitech has converted its option into an exclusive worldwide license for the novel vaccine delivery technology, Troybodies. The company made the decision after early investigations demonstrated the ability of the technology to elicit a specific cellular immune response in vivo.
Affitech secured an exclusive option to Troybodies from the technology's inventors at the University of Oslo and the Norwegian National Hospital. This option will now be converted to an exclusive worldwide licence with unrestricted sublicense rights. As part of the option agreement, Affitech will enter into a research and development plan with the University of Oslo on cancer and autoimmunity.
The Troybodies technology utilizes specially engineered antibodies to position candidate antigenic T cell epitopes on MHC class II molecules of antigen presenting cells (APCs). This mechanism has been likened to a Trojan horse, as the T cell epitopes are hidden within ...